LipimetiX is focused on the cost-efficient development of its technology through a virtual company structure under the leadership of experienced scientists and biotech business executives, through a partnership between Benu BioPharma and Capstone Therapeutics. >> Read More
The Apo E mimetics were developed through the intimate knowledge of structure and function of the amphipathic helix in Apolipoproteins.
>> Read More
Capstone Therapeutics Announces Phase 1b/2a Study Results for AEM-28 Showing Safety and Biomarker Efficacy Signals
>> Read More
LipimetiX Development was established as a joint venture between Capstone Therapeutics Corp. (OTCQB: CAPS), and LipimetiX, Inc.
We are a privately held biopharmaceutical company created to develop a class of drugs to treat refractory hypercholesterolemia, coronary artery, and peripheral artery diseases by rapidly decreasing arterial cholesterol content and inflammation. LipimetiX's technology is based upon small peptide mimetics of Apolipoprotein E, a critical protein that directs cholesterol and triglyceride rich lipoproteins to receptors on the liver. LipimetiX's lead peptide, AEM-28, is currently being developed for genetically induced refractory hypercholesterolemia, an orphan indication that leads to early cardiovascular disease. AEM-28 has been granted orphan drug designation from the FDA.